Navigation Links
Targeted therapy prolongs life in patients with HER2-positive breast cancer
Date:12/11/2009

SAN ANTONIO Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumors are HER2-positive, according to Kimberly Blackwell, M.D., associate professor of medicine at Duke University Medical Center. Blackwell presented the findings today at the CTRC-AACR San Antonio Breast Cancer Symposium.

Blackwell says the combination targeted therapy gave patients more than a four-month survival advantage over those who took lapatinib alone. She says the findings may be the first step toward a chemotherapy-free future.

"This is the first time that a pair of targeted therapies has been shown to be superior to any intervention that paired a targeted therapy with a hormonal or chemotherapy based approach," she said.

The results stem from a large, Phase III clinical trial where investigators randomized 296 patients with metastatic breast cancer to receive either lapatinib (also known as Tykerb) alone or lapatinib plus trastuzumab (Herceptin) once a day. All participants had metastatic disease that had continued to spread even after treatments with several interventions that included trastuzumab plus chemotherapy.

Blackwell says trastuzumab binds to and blocks part of the HER2 growth factor that appears on the surface of some breast cancer cells while lapatinib binds to a second growth factor, EGFR, and part of HER2 that sits below the cell surface. "It's sort of a double whammy, disabling the HER2 protein in two places instead of one."

Women who enrolled in the single-agent arm of the study and whose cancer continued to spread after four weeks were allowed to cross over to the other arm of the study to continue on the combined approach.

Fifty-two percent of the women enrolled in the lapatinib-only arm of the study crossed over to the combination arm. The median overall survival following treatment with lapatinib plus trastuzumab was 60.7 weeks comp
'/>"/>

Contact: Michelle Gailiun
michelle.gailiun@duke.edu
919-724-5343
Duke University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Targeted Breast Ultrasound Can Reduce Biopsies for Women Under Forty
2. Targeted breast ultrasound can reduce biopsies for women under 40
3. Targeted Testing Receives Favorable Reviews On PADDS, Begins Nationwide Research Study On The Target Tests of Executive Functioning-OV
4. Reportlinker Adds The Future of Senior Nutrition: Key Ingredients, Strategic Issues and Targeted Opportunities for Older Consumers
5. Hard To Treat Diseases (HTDS) Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger
6. Senate Votes to Proceed - 60 Plus Announces New 9 State TV Campaign Targeted at Senators to Protect Medicare
7. AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer
8. Targeted heat therapy offers new standard treatment option for soft tissue sarcoma
9. Narconon Launches Operation Medicine Cabinet in Georgia - Prescription Drugs Commonly Abused Targeted
10. Argonne, University of Chicago Scientists Develop Targeted Cancer Treatment Using Nanomaterials
11. Argonne, University of Chicago scientists develop targeted cancer treatment using nanomaterials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, 2015 , ... ... and InHealth Media. Nutritional Products International and InHealth media is a global sales ... , “We are extremely pleased to continue our business relationship with Mr. Reid ...
(Date:8/30/2015)... ... August 30, 2015 , ... ... devices for the treatment of prostate cancer, has announced the roll-out of its ... the treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently in ...
(Date:8/29/2015)... ... August 30, 2015 , ... Electronic Informed Consent for ... 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The simple fact about electronic informed ... , Clinical trial sites can now use audio, video and interactivity to ...
(Date:8/29/2015)... ... August 29, 2015 , ... It ... and protection against dribbled urine and sweat. "In order to prevent these problems, ... The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support for a male’s ...
(Date:8/29/2015)... ... ... like Toppik , Eau Thermale Avene and Bliss are now available on ... required to qualify for free standard shipping,” said Jennifer Ramirez, the public relations manager. ... the item’s selling price.” , With competitive pricing in the e-commerce market for beauty ...
Breaking Medicine News(10 mins):Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2
... Leicester and the University of Ferrara in Italy have collaborated ... cancer pain without causing many of the side effects of ... 90% of cancer patients experience pain in the final year ... the use of drugs like morphine produces side effects such ...
... appendicitis are often diffuse and it can be difficult to ... disease. It may be possible to predict the severity from ... on an individual basis. This is the conclusion of a ... know what causes appendicitis. There is evidence that the cause ...
... didn,t accurately diagnose elderly Asians, study found , MONDAY, ... year by the American Diabetes Association as an effective ... of Singapore suggests that the hemoglobin A1c blood test ... , The American Diabetes Association,s current recommendation is that ...
... ... well as the degree programs, you don,t need to look too far. A comprehensive guide ... useful awaits you at EducationCenters.com. A stop shop for all your education needs, this site ... , ...
... Reza ... as Exclusive Distributor/Manufacturer for Saudi Arabia and the Middle East, , ... Newark, NJ (PRWEB) June 21, 2010 -- BioNeutral Group ... Chief Scientist, Dr. Andy Kielbania, will assist with a similar role in Steri – 7, ...
... ... Enterprise Mobile Management drives down support costs, improves performance and service quality of mobility ... has made available a complimentary copy of the report in the link below. ... (PRWEB) June 21, ...
Cached Medicine News:Health News:New drugs to relieve cancer pain 2Health News:New possibility to determine the severity of appendicitis 2Health News:Age, Race May Affect Type 2 Diabetes Screening Results 2Health News:The Epicenter of Education Information is Not Too Far Away 2Health News:BioNeutral Chief Scientist Dr. Andy Kielbania Appointed to Steri - 7 for Expanded Role 2Health News:BioNeutral Chief Scientist Dr. Andy Kielbania Appointed to Steri - 7 for Expanded Role 3Health News:BioNeutral Chief Scientist Dr. Andy Kielbania Appointed to Steri - 7 for Expanded Role 4Health News:Industry Benchmark Report Finds Full Mobile Lifecycle Management and ITSM Critical to Enterprise Mobile Management 2Health News:Industry Benchmark Report Finds Full Mobile Lifecycle Management and ITSM Critical to Enterprise Mobile Management 3Health News:Industry Benchmark Report Finds Full Mobile Lifecycle Management and ITSM Critical to Enterprise Mobile Management 4
(Date:8/28/2015)... , Aug. 28, 2015  CytomX Therapeutics, Inc., a ... cancer, today announced the filing of a registration statement ... Commission (SEC) relating to a proposed initial public offering ... be offered and the price range for the offering ... its common stock under the symbol "CTMX" on the ...
(Date:8/28/2015)... 28, 2015 Research ... addition of the "12th Annual Report and ... report to their offering. The 2015 ... Capacity and Production is the most recent study ... and projected future capacity and production. The report ...
(Date:8/28/2015)... Research and Markets ... the "Investigation Report on China,s Quetiapine Market, ... Developed by AstraZeneca plc, quetiapine (under the trade ... the treatment of schizophrenia. Approved by CFDA to ... the Catalogue of Drugs for the Basic National ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2China Quetiapine Market Investigation Report 2010-2019 2
... COMBINATION WITH DIURETIC ACCEPTED FOR REVIEW BY,FDA- , ... 2007 -,Speedel (SWX: SPPN) today welcomed the significant ... by investigators at the 22nd Annual Scientific Meeting,and ... in,Chicago, IL, USA. These results confirm the favourable ...
... inflammation in models of,arthritis and Salmonella infection, ... -, WASHINGTON, May 21, 2007 /PRNewswire/ -- ... from two studies,that demonstrate the anti-inflammatory activity ... origin, Bifantis(R),(Bifidobacterium infantis 35624), in models of ...
Cached Medicine Technology:New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 2New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 3New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 4New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 5New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 6New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 7New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 8New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 9New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 10New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 11New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory,Properties and Increased Health Benefits 2New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory,Properties and Increased Health Benefits 3
... The Videoscopes provide superior image ... connecting to the camera head with ... density ensures more light at the ... provide optimum image clarity and reliability.,The ...
... Passport II delivery device is the second ... C11UB. Its simple-to-use syringe technology allows one-handed ... small incision. The blue colored plunger allows ... protect the haptics during insertion. The modified ...
... for long-term transtelephonic monitoring. Simple to use, ... in order to record all pre and post ... button, the patient sends the recorded ECG over ... for immediate diagnosis. Use of Heart 2005A is ...
... IMPACs comprehensive information system designed specifically ... integrate and streamline their diagnostic, management, ... intuitive software solution. Thousands of laboratory ... have proven PowerPaths unique "case-centric model ...
Medicine Products: